Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus

被引：31
作者：
DeZure, Adam D. [1 ]
Berkowitz, Nina M. [1 ]
Graham, Barney S. [1 ]
Ledgerwood, Julie E. [1 ]
机构：
[1] NIAID, Vaccine Res Ctr, NIH, 40 Convent Dr,Rm 5512, Bethesda, MD 20892 USA
来源：
JOURNAL OF INFECTIOUS DISEASES | 2016年 / 214卷
基金：
美国国家卫生研究院;
关键词：
chikungunya virus; vaccine; whole-inactivated vaccine; virus-like particle vaccine; alphavirus; COMPARATIVE IMMUNOGENICITIES; PROTECTS MICE; REEMERGENCE; CANDIDATE; INFECTION; DISEASE; SAFETY; TRIAL;
D O I：
10.1093/infdis/jiw352
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Chikungunya virus (CHIKV) is a global public health threat, having been identified in >60 countries in Asia, Africa, Europe, and the Americas. There is no cure for or licensed vaccine against CHIKV infection. Initial attempts at CHIKV vaccine development began in the early 1960s. Whole-inactivated and virus-like particle (VLP) vaccines are 2 of the current approaches being evaluated. Success of these approaches is dependent on a safe, well-tolerated vaccine that is immunogenic and deployable in regard to manufacturing, stability, and delivery characteristics.
引用
收藏
页码：S497 / S499
页数：3
相关论文
共 38 条
[1]   A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection [J].
Akahata, Wataru ;
Yang, Zhi-Yong ;
Andersen, Hanne ;
Sun, Siyang ;
Holdaway, Heather A. ;
Kong, Wing-Pui ;
Lewis, Mark G. ;
Higgs, Stephen ;
Rossmann, Michael G. ;
Rao, Srinivas ;
Nabel, Gary J. .
NATURE MEDICINE, 2010, 16 (03) :334-U134
[2]   A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus [J].
Brandler, Samantha ;
Ruffle, Claude ;
Combredet, Chantal ;
Brault, Jean-Baptiste ;
Najburg, Valerie ;
Prevost, Marie-Christine ;
Habel, Andre ;
Tauber, Erich ;
Despres, Philippe ;
Tangy, Frederic .
VACCINE, 2013, 31 (36) :3718-3725
[3]   Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial [J].
Chang, Lee-Jah ;
Dowd, Kimberly A. ;
Mendoza, Floreliz H. ;
Saunders, Jamie G. ;
Sitar, Sandra ;
Plummer, Sarah H. ;
Yamshchikov, Galina ;
Sarwar, Uzma N. ;
Hu, Zonghui ;
Enama, Mary E. ;
Bailer, Robert T. ;
Koup, Richard A. ;
Schwartz, Richard M. ;
Akahata, Wataru ;
Nabel, Gary J. ;
Mascola, John R. ;
Pierson, Theodore C. ;
Graham, Barney S. ;
Ledgerwood, Julie E. .
LANCET, 2014, 384 (9959) :2046-2052
[4]   CHIKUNGUNYA VIRUS VACCINE PREPARED BY TWEEN-ETHER EXTRACTION [J].
ECKELS, KH ;
HARRISON, VR ;
HETRICK, FM .
APPLIED MICROBIOLOGY, 1970, 19 (02) :321-&
[5]   Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218 [J].
Edelman, R ;
Tacket, CO ;
Wasserman, SS ;
Bodison, SA ;
Perry, JG ;
Mangiafico, JA .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2000, 62 (06) :681-685
[6]   A Novel Poxvirus-Based Vaccine, MVA-CHIKV, Is Highly Immunogenic and Protects Mice against Chikungunya Infection [J].
Garcia-Arriaza, Juan ;
Cepeda, Victoria ;
Hallengaerd, David ;
Sorzano, Carlos Oscar S. ;
Kuemmerer, Beate Mareike ;
Liljestroem, Peter ;
Esteban, Mariano .
JOURNAL OF VIROLOGY, 2014, 88 (06) :3527-3547
[7]   Chikungunya Virus Arthritis in Adult Wild-Type Mice [J].
Gardner, Joy ;
Anraku, Itaru ;
Le, Thuy T. ;
Larcher, Thibaut ;
Major, Lee ;
Roques, Pierre ;
Schroder, Wayne A. ;
Higgs, Stephen ;
Suhrbier, Andreas .
JOURNAL OF VIROLOGY, 2010, 84 (16) :8021-8032
[8]   Virus-like particles: Passport to immune recognition [J].
Grgacic, Elizabeth V. L. ;
Anderson, David A. .
METHODS, 2006, 40 (01) :60-65
[9]   Prime-Boost Immunization Strategies against Chikungunya Virus [J].
Hallengard, David ;
Lum, Fok-Moon ;
Kuemmerer, Beate M. ;
Lulla, Aleksei ;
Lulla, Valeria ;
Garcia-Arriaza, Juan ;
Fazakerley, John K. ;
Roques, Pierre ;
Le Grand, Roger ;
Merits, Andres ;
Ng, Lisa F. P. ;
Esteban, Mariano ;
Liljestrom, Peter .
JOURNAL OF VIROLOGY, 2014, 88 (22) :13333-13343
[10]  
HARRISON VR, 1971, J IMMUNOL, V107, P643
1234